thumbnail
Deal MakingAlmirall licenses Novo’s mAb to treat dermatological diseasesAlmirall licenses Novo’s mAb to treat dermatological diseases
Novo Nordisk has out-licensed the rights for its IL-21 blocking monoclonal antibody (mAb) NN-8828 to Almirall, a dermatology company.